BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 34980002)

  • 1. The impact of young age (< 40 years) on the outcome of a cohort of patients with primary non-metastatic breast cancer: analysis of 10-year survival of a prospective study.
    Bouferraa Y; Haibe Y; Chedid A; Jabra E; Charafeddine M; Temraz S; Mukherji D; El Saghir N; Shamseddine A
    BMC Cancer; 2022 Jan; 22(1):27. PubMed ID: 34980002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
    Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
    Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
    Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.
    Foulkes WD; Chappuis PO; Wong N; Brunet JS; Vesprini D; Rozen F; Yuan ZQ; Pollak MN; Kuperstein G; Narod SA; Bégin LR
    Ann Oncol; 2000 Mar; 11(3):307-13. PubMed ID: 10811497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Younger age is an independent predictor of worse prognosis among Lebanese nonmetastatic breast cancer patients: analysis of a prospective cohort.
    El Chediak A; Alameddine RS; Hakim A; Hilal L; Abdel Massih S; Hamieh L; Mukherji D; Temraz S; Charafeddine M; Shamseddine A
    Breast Cancer (Dove Med Press); 2017; 9():407-414. PubMed ID: 28670139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
    BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
    Gonzalez-Angulo AM; Timms KM; Liu S; Chen H; Litton JK; Potter J; Lanchbury JS; Stemke-Hale K; Hennessy BT; Arun BK; Hortobagyi GN; Do KA; Mills GB; Meric-Bernstam F
    Clin Cancer Res; 2011 Mar; 17(5):1082-9. PubMed ID: 21233401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
    Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of female breast cancer according to BRCA mutation status.
    Cronin-Fenton DP; Kjærsgaard A; Nørgaard M; Pedersen IS; Thomassen M; Kaye JA; Gutierrez L; Telford C; Lewis J; Tyczynski JE; Sørensen HT
    Cancer Epidemiol; 2017 Aug; 49():128-137. PubMed ID: 28601786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia.
    Budroni M; Cesaraccio R; Coviello V; Sechi O; Pirino D; Cossu A; Tanda F; Pisano M; Palomba G; Palmieri G
    BMC Cancer; 2009 Feb; 9():62. PubMed ID: 19232099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA-associated breast cancer in young women.
    Robson M; Gilewski T; Haas B; Levin D; Borgen P; Rajan P; Hirschaut Y; Pressman P; Rosen PP; Lesser ML; Norton L; Offit K
    J Clin Oncol; 1998 May; 16(5):1642-9. PubMed ID: 9586873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
    Baretta Z; Mocellin S; Goldin E; Olopade OI; Huo D
    Medicine (Baltimore); 2016 Oct; 95(40):e4975. PubMed ID: 27749552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
    Bayraktar S; Gutierrez-Barrera AM; Liu D; Tasbas T; Akar U; Litton JK; Lin E; Albarracin CT; Meric-Bernstam F; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
    Breast Cancer Res Treat; 2011 Nov; 130(1):145-53. PubMed ID: 21830012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer.
    Cubukcu E; Kanat O; Fatih Olmez O; Kabul S; Canhoroz M; Avci N; Deligonul A; Hartavi M; Cubukcu S; Olmez F; Kurt E; Evrensel T; Gokgoz S; Manavoglu O
    J BUON; 2013; 18(2):359-65. PubMed ID: 23818346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.
    Vos S; Elias SG; van der Groep P; Smolders YH; van Gils CH; van Diest PJ
    Am J Surg Pathol; 2018 Sep; 42(9):1262-1272. PubMed ID: 29979200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy After Breast Cancer in Patients With Germline
    Lambertini M; Ameye L; Hamy AS; Zingarello A; Poorvu PD; Carrasco E; Grinshpun A; Han S; Rousset-Jablonski C; Ferrari A; Paluch-Shimon S; Cortesi L; Senechal C; Miolo G; Pogoda K; Pérez-Fidalgo JA; De Marchis L; Ponzone R; Livraghi L; Estevez-Diz MDP; Villarreal-Garza C; Dieci MV; Clatot F; Berlière M; Graffeo R; Teixeira L; Córdoba O; Sonnenblick A; Luna Pais H; Ignatiadis M; Paesmans M; Partridge AH; Caron O; Saule C; Del Mastro L; Peccatori FA; Azim HA
    J Clin Oncol; 2020 Sep; 38(26):3012-3023. PubMed ID: 32673153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China.
    Deng M; Chen HH; Zhu X; Luo M; Zhang K; Xu CJ; Hu KM; Cheng P; Zhou JJ; Zheng S; Chen YD
    Int J Cancer; 2019 Sep; 145(6):1517-1528. PubMed ID: 30720863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.